市場調査レポート
商品コード
1439259

経皮ドラッグデリバリーデバイスの世界市場:洞察、競合情勢、市場予測:2030年

Transdermal Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
経皮ドラッグデリバリーデバイスの世界市場:洞察、競合情勢、市場予測:2030年
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の経皮ドラッグデリバリーデバイスの市場規模は、2024年から2030年までの予測期間中に9.8%のCAGRで拡大すると予測されています。経皮ドラッグデリバリーデバイスの需要は、主に、慢性疾患の有病率の増加、第3世代の経皮ドラッグデリバリーデバイスの採用の増加、デバイスで観察された技術的進歩、ホルモン障害から心血管疾患や疼痛管理へのこれらのデバイスの使用を理由に成長が促進されています。

米国心臓協会(American Heart Association 2022)によると、2020年には全世界で約2億4,410万人が冠動脈性(虚血性)心疾患を患っています。同出典によると、北アフリカ、中東、中央アジア、南アジア、東欧は、2020年に世界で冠動脈性(虚血性)心疾患の有病率が最も高くなっています。

国際アルツハイマー病協会(Alzheimer's Disease International 2020)によると、2020年には世界で5,500万人以上が認知症に罹患しています。その数は20年ごとに倍増し、2030年には8,200万人、2050年には1億5,200万人に達すると予想されています。

片頭痛研究財団によると、2020年には、片頭痛は世界で3番目に多い病気になるといいます。片頭痛は、米国では3,900万人、世界では10億人の男性、女性、子供が罹患している、非常に有病率の高い神経疾患です。したがって、中枢神経系疾患、心血管疾患などの慢性疾患の症例数の増加により、経皮ドラッグデリバリーデバイスの需要が増加し、経皮ドラッグデリバリーデバイスの市場をさらに拡大させると予測されています。

当レポートでは、世界の経皮ドラッグデリバリーデバイス市場について調査し、市場の概要とともに、タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 経皮ドラッグデリバリーデバイスレポートのイントロダクション

第2章 経皮ドラッグデリバリーデバイスのエグゼクティブサマリー

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 経皮ドラッグデリバリーデバイスの主な要因分析

  • 経皮ドラッグデリバリーデバイス市場の促進要因
  • 経皮ドラッグデリバリーデバイス市場の抑制要因と課題
  • 経皮ドラッグデリバリーデバイス市場の機会

第5章 経皮ドラッグデリバリーデバイスにおけるポーターのファイブフォース分析

第6章 経皮ドラッグデリバリーデバイス市場の概要

  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第7章 経皮ドラッグデリバリーデバイスの企業と製品プロファイル

  • Hisamitsu Pharmaceutical
  • Mylan
  • UCB SA
  • Novartis
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Endo International
  • Purdue Pharma
  • Bristol-Myers Squibb Company
  • Endo Pharmaceuticals Inc.
  • Acrux Limited
  • Lavipharm
  • Lead Chemicals Co. Inc.
  • Luye Pharma Group

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 DelveInsightのサービス内容

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Transdermal Drug Delivery Devices Market in Global (2021-2030)
  • Table 3: Transdermal Drug Delivery Devices Market in Global by Type (2021-2030)
  • Table 4: Transdermal Drug Delivery Devices Market in Global by Application (2021-2030)
  • Table 5: Transdermal Drug Delivery Devices Market in Global by End-User (2021-2030)
  • Table 6: Transdermal Drug Delivery Devices Market in Global by Geography (2021-2030)
  • Table 7: Transdermal Drug Delivery Devices Market in North America (2021-2030)
  • Table 8: Transdermal Drug Delivery Devices Market in the US (2021-2030)
  • Table 9: Transdermal Drug Delivery Devices Market in Canada (2021-2030)
  • Table 10: Transdermal Drug Delivery Devices Market in Mexico (2021-2030)
  • Table 11: Transdermal Drug Delivery Devices Market in Europe (2021-2030)
  • Table 12: Transdermal Drug Delivery Devices Market in France (2021-2030)
  • Table 13: Transdermal Drug Delivery Devices Market in Germany (2021-2030)
  • Table 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2021-2030)
  • Table 15: Transdermal Drug Delivery Devices Market in Italy (2021-2030)
  • Table 16: Transdermal Drug Delivery Devices Market in Spain (2021-2030)
  • Table 17: Transdermal Drug Delivery Devices Market in Rest of Europe (2021-2030)
  • Table 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2021-2030)
  • Table 19: Transdermal Drug Delivery Devices Market in China (2021-2030)
  • Table 20: Transdermal Drug Delivery Devices Market in Japan (2021-2030)
  • Table 21: Transdermal Drug Delivery Devices Market in India (2021-2030)
  • Table 22: Transdermal Drug Delivery Devices Market in Australia (2021-2030)
  • Table 23: Transdermal Drug Delivery Devices Market in South Korea (2021-2030)
  • Table 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 25: Transdermal Drug Delivery Devices Market in Rest of World (2021-2030)
  • Table 26: Transdermal Drug Delivery Devices Market in Middle East (2021-2030)
  • Table 27: Transdermal Drug Delivery Devices Market in Africa (2021-2030)
  • Table 28: Transdermal Drug Delivery Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Transdermal Drug Delivery Devices Market in Global (2021-2030)
  • Figure 3: Transdermal Drug Delivery Devices Market in Global by Type (2021-2030)
  • Figure 4: Transdermal Drug Delivery Devices Market in Global by Application (2021-2030)
  • Figure 5: Transdermal Drug Delivery Devices Market in Global by End-User (2021-2030)
  • Figure 6: Transdermal Drug Delivery Devices Market in Global by Geography (2021-2030)
  • Figure 7: Transdermal Drug Delivery Devices Market in North America (2021-2030)
  • Figure 8: Transdermal Drug Delivery Devices Market in the US (2021-2030)
  • Figure 9: Transdermal Drug Delivery Devices Market in Canada (2021-2030)
  • Figure 10: Transdermal Drug Delivery Devices Market in Mexico (2021-2030)
  • Figure 11: Transdermal Drug Delivery Devices Market in France (2021-2030)
  • Figure 12: Transdermal Drug Delivery Devices Market in Germany (2021-2030)
  • Figure 13: Transdermal Drug Delivery Devices Market in the United Kingdom (2021-2030)
  • Figure 14: Transdermal Drug Delivery Devices Market in Italy (2021-2030)
  • Figure 15: Transdermal Drug Delivery Devices Market in Spain (2021-2030)
  • Figure 17: Transdermal Drug Delivery Devices Market in Rest of Europe (2021-2030)
  • Figure 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2021-2030)
  • Figure 19: Transdermal Drug Delivery Devices Market in China (2021-2030)
  • Figure 20: Transdermal Drug Delivery Devices Market in Japan (2021-2030)
  • Figure 21: Transdermal Drug Delivery Devices Market in India (2021-2030)
  • Figure 22: Transdermal Drug Delivery Devices Market in Australia (2021-2030)
  • Figure 23: Transdermal Drug Delivery Devices Market in South Korea (2021-2030)
  • Figure 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
  • Figure 25: Transdermal Drug Delivery Devices Market in Rest of World (2021-2030)
  • Figure 26: Transdermal Drug Delivery Devices Market in Middle East (2021-2030)
  • Figure 27: Transdermal Drug Delivery Devices Market in Africa (2021-2030)
  • Figure 28: Transdermal Drug Delivery Devices Market in South America (2021-2030)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Market Opportunities
  • Figure 32: PORTER'S Five Forces Analysis
目次
Product Code: DIMDCL0048

Transdermal Drug Delivery Devices Market By Type (Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Hormonal Applications, Central Nervous System Disorders, Cardiovascular Diseases, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence observed in chronic conditions and the increasing demand for third-generation transdermal drug delivery devices.

The global transdermal drug delivery devices market is growing at a CAGR of 9.8% during the forecast period from 2024 to 2030. The demand for transdermal drug delivery devices is primarily witnessing growth on account of the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and the use of these devices from hormonal disorders to cardiovascular conditions and pain management.

Transdermal Drug Delivery Devices Market Dynamics:

According to the American Heart Association 2022, globally, about 244.1 million people were living with coronary (ischemic) heart disease in 2020. As per the same source, North Africa, the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rates of coronary (ischemic) heart disease in the world in 2020.

According to Alzheimer 's Disease International 2020, worldwide more than 55 million people were suffering from dementia in 2020. The numbers are expected to double every 20 years, reaching 82 million in 2030 and 152 million in 2050.

According to the Migraine Research Foundation, in 2020, migraine accounts to be the third most prevalent illness in the world. It is an extraordinarily prevalent neurological disease, affecting 39 million men, women, and children in the US and 1 billion worldwide. Hence, due to an increase in the number of cases of chronic diseases such as central nervous system disorders, cardiovascular diseases, and others, there will be an increase in demand for transdermal drug delivery devices, fueling the market for transdermal drug delivery devices.

However, certain disadvantages associated with transdermal drug delivery devices such as irritation at the site of application and edema, and certain drugs carrying hydrophilic structures tend to penetrate the skin slowly and do not achieve actual therapeutic levels. These factors are expected to limit the market growth over the forecast period.

Transdermal Drug Delivery Devices Market Segment Analysis:

Transdermal Drug Delivery Devices Market by Type (Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Hormonal Applications, Central Nervous System Disorders, Cardiovascular Diseases, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the application segment of the transdermal drug delivery devices market, pain management can be expected to achieve the largest market share. The reason for this is the rising burden of chronic pain conditions worldwide and the rising availability of transdermal products in the field of pain management.

According to the Centers for Disease Control and Prevention (CDC)/National Center for Health Statistics 2020, about 20.4% of adults had chronic pain in 2019 in the US. As per the same source, 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high-impact chronic pain) in the past 3 months.

Pain affects the quality of life of a person and interferes with the daily activities of an individual. Transdermal drug delivery devices can help in the effective management of pain.

The rise in the prevalence of chronic pain conditions will demand more transdermal drug delivery devices for the management of pain, thereby fueling the transdermal drug delivery devices market growth.

North America is expected to dominate the Overall Transdermal Drug Delivery Devices Market:

Among all the regions, North America is expected to account for the largest share of the transdermal drug delivery devices market. This can be attributed to the rising prevalence of chronic pain, central nervous system disorders, and cardiovascular disorders in the region, the rising use of contraceptives, and the increase in research-related activities of transdermal drug delivery systems are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.

The American Heart Association in 2021 projected that by 2035, more than 130 million US adults will have some type of heart disease.

As per the data provided by the Alzheimer Association (2023), more than 6 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. The Parkinson's Foundation 2022 data states that every year 90,000 people are diagnosed with Parkinson's in the United States.

The rise in the number of chronic conditions in North America can be thought of to cause a surge in the transdermal drug delivery market within this region.

Transdermal Drug Delivery Devices Market Key Players:

Some of the key market players operating in the transdermal drug delivery devices market include Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Endo International, Purdue Pharma, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Acrux Limited, Lavipharm, Lead Chemicals Co. Inc., Luye Pharma Group and others.

Recent Developmental Activities in Transdermal Drug Delivery Devices Market:

In July 2020, Hisamitsu Pharmaceutical Co., Inc. announced that it has obtained approval for manufacturing and marketing OABLOK® PATCH in Thailand.

Key Takes Away from the Transdermal Drug Delivery Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global transdermal drug delivery devices market.

Various opportunities available for the other competitor in the transdermal drug delivery devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?

Target Audience who can be benefited from the Transdermal Drug Delivery Devices Market Report Study

Transdermal Drug Delivery Devices providers

Research organizations and consulting companies

Transdermal Drug Delivery Devices-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders

Various End-Users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.

Frequently Asked Questions for Transdermal Drug Delivery Devices Market:

1. What are transdermal drug delivery devices?

Transdermal drug delivery is a procedure that provides drug absorption via the skin. The transdermal drug delivery system is used for the delivery of small, lipophilic, low-dose drugs.

2. What is the market for global transdermal drug delivery devices?

The global transdermal drug delivery devices market is growing at a CAGR of 9.8% during the forecast period from 2024 to 2030.

3. What are the drivers for global transdermal drug delivery devices?

The major drivers driving the demand for transdermal drug delivery devices are the rising prevalence of chronic conditions, rising adoption of third-generation transdermal drug delivery devices, increase in technological advancements observed in the device, and the use of these devices from hormonal disorders to cardiovascular conditions and pain management.

4. Who are the key players operating in global transdermal drug delivery devices?

Some of the key market players operating in the transdermal drug delivery devices market include Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Endo International, Purdue Pharma, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., and others.

5. Which region has the highest share in the transdermal drug delivery devices market?

North America is expected to dominate the overall transdermal drug delivery devices market during the forecast period, 2024 to 2030. This domination is due to the rising prevalence of chronic pain, central nervous system disorders, and cardiovascular disorders in the region, the rising use of contraceptives, and the increase in research-related activities of transdermal drug delivery systems in the North American region.

Table of Contents

1. Transdermal Drug Delivery Devices Report Introduction

2. Transdermal Drug Delivery Devices Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Transdermal Drug Delivery Devices Key Factors Analysis

  • 4.1. Transdermal Drug Delivery Devices Market Drivers
    • 4.1.1. Increasing prevalence of chronic conditions
    • 4.1.2. Increase in adoption of third-generation transdermal drug delivery devices
    • 4.1.3. Technological advancements observed in the device
    • 4.1.4. Use of these devices from hormonal disorders to cardiovascular conditions and pain management
  • 4.2. Transdermal Drug Delivery Devices Market Restraints and Challenges
    • 4.2.1. Certain disadvantages associated with the transdermal drug delivery devices such as irritation at the site of application and edema
    • 4.2.2. Certain drugs carrying hydrophilic structures tend to penetrate the skin slowly and do not achieve actual therapeutic levels
  • 4.3. Transdermal Drug Delivery Devices Market Opportunities
    • 4.3.1. Increasing awareness towards transdermal drug delivery devices
    • 4.3.2. Increased patient adoption for pain-less transdermal drug delivery devices

5. Transdermal Drug Delivery Devices Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Transdermal Drug Delivery Devices Market Layout

  • 6.1. By Type
    • 6.1.1. Drug-in-adhesive Patches
    • 6.1.2. Matrix Patches
    • 6.1.3. Reservoir Membrane Patches
    • 6.1.4. Microneedle Patches
  • 6.2. By Application
    • 6.2.1. Pain Management
    • 6.2.2. Central Nervous System Disorders
    • 6.2.3. Hormonal Applications
    • 6.2.4. Cardiovascular Diseases
    • 6.2.5. Others
  • 6.3. By End-User
    • 6.3.1. Hospitals
    • 6.3.2. Ambulatory Surgical Centers
    • 6.3.3. Others
  • 6.4. By Geography
    • 6.4.1. North America Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.1.1. United States Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.1.2. Canada Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.1.3. Mexico Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.4.2. Europe Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.2.1. France Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.2.2. Germany Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.2.3. United Kingdom Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.2.4. Italy Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.2.5. Spain Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.2.6. Rest of Europe Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.4.3. Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.3.1. China Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.3.2. Japan Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.3.3. India Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.3.4. Australia Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.3.5. South Korea Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.3.6. Rest of Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.4.4. Rest of the World (RoW) Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.4.1. Middle East Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.4.2. Africa Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.4.4.3. South America Transdermal Drug Delivery Devices Market Size in USD million (2021-2030)

7. Transdermal Drug Delivery Devices Company and Product Profiles

  • 7.1. Hisamitsu Pharmaceutical
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Mylan
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. UCB SA
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Novartis
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. GlaxoSmithKline
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Boehringer Ingelheim
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Johnson & Johnson
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Endo International
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Purdue Pharma
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Bristol-Myers Squibb Company
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Endo Pharmaceuticals Inc.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Acrux Limited
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Lavipharm
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Lead Chemicals Co. Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Luye Pharma Group
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. DelveInsight Capabilities

12. Disclaimer & Contact Us